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INTRODUCTION
World Population Prospects: the 2015 Revision (United Nations, 
2015) reported that the population of older persons, those aged 
60 years or over, has substantially increased in most countries, and 
this growth is expected to accelerate in the coming decades [1]. 
Another study also reported that by 2050, the world’s population 
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recovery after aging-induced cognitive decline. Taken together, these results suggest that the newly synthesized AMPK activator, 
HL271, could be a potential therapeutic agent to treat age-related cognitive decline.
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aged 60 years and older is projected to reach 2 billion, increasing 
from 900 million in 2015 [2]. Moreover, the population of those 
aged 80 years or over is growing even faster, and within this age 
group, approximately 50% to over 60% are estimated to have de-
mentia [3]. Therefore, in recent years, aging-induced cognitive im-
pairments including dementia and Alzheimer’s disease (AD) have 
become the biggest challenges for global public health and social 
care. Therefore, the development of potential therapeutic drugs for 
aging-associated cognitive impairment is essential.
Metabolic dysregulation is a key factor that affects both ag-
ing and dementia [4, 5]. Indeed, the incidence of both T2DM, a 
metabolic disorder, and dementia increases with aging, and the 
prevalence of mild cognitive impairment (MCI) and dementia, in-
cluding AD, is higher in individuals with diabetes [6, 7]. Increased 
blood glucose levels in T2DM patients has been widely accepted 
to lead to medical complications, including negative influences 
on cognition [8-10]. Therefore, the use of antidiabetic medica-
tions for the management of various cognitive dysfunctions has 
received more attention. Some oral antidiabetic medications have 
been evaluated for their efficacy in improving cognitive function 
in MCI and AD patients [11]. Intranasal insulin treatment has also 
been shown to improve the memory and cognitive abilities of pa-
tients with MCI and AD [12, 13]. Whether diabetes management 
can reduce the incidence of MCI and AD in the elderly remains 
uncertain; however, emerging lines of evidence suggest that diabe-
tes therapies may have the potential to improve cognitive function 
[14-16].
For a recently initiated clinical trial called “Targeting Aging with 
Metformin” (TAME) supported by an R24 grant from the National 
Institute on Aging (NIA; J. Kirkland, N.B., S. Austad), Barzilai 
and colleagues chose metformin to target aging and its diseases 
including dementia and AD in humans for several reasons [17]. 
Metformin modulates metabolic and cellular processes including 
mitochondrial function [18], which is closely associated with the 
development of age-related conditions. Human clinical trials and 
observational studies have shown that metformin treatment is also 
beneficial for other age-related diseases such as cardiovascular 
disease (CVD) [19] and cancer [20]. More importantly, a grow-
ing body of evidence suggests that metformin is associated with a 
reduction in cognitive impairments in both T2DM patients [21] 
and non-diabetic subjects [22]. Furthermore, several studies have 
reported an association between metformin and decreased mor-
tality [23]. In addition to those positive aspects of metformin in 
aging, metformin has been used with an outstanding safety record 
for over 60 years [17]. Thus, metformin is now seen as one of the 
most promising drugs to target aging and its associated diseases 
including dementia and AD. However, no definitive trials have 
been conducted to evaluate the efficacy of metformin in cognitive 
dysfunction in the elderly [17]. Therefore, separate studies should 
be performed to verify the effectiveness of metformin in attenuat-
ing cognitive impairments in the elderly and to understand related 
cellular mechanisms.
Metformin belongs to a class of drugs called biguanides, an or-
ganic compound with the formula HN(C(NH)NH2)2 and is cur-
rently the most widely prescribed drug for the treatment of type 2 
diabetes [24, 25]. The commonly accepted mechanism underlying 
the anti-hyperglycemic effects of metformin is the suppression of 
hepatic glucose production via the activation of adenosine mo-
nophosphate (AMP)-activated protein kinase (AMPK), the pri-
mary energy sensor and regulator of energy homeostasis [26, 27]. 
AMPK is a highly conserved serine/threonine protein kinase con-
sisting of a catalytic α subunit and two regulatory β and γ subunits 
and is activated in response to an increase in the AMP: adenosine 
triphosphate (ATP) ratio in metabolic stress conditions, such as 
hypoxia, ischemia or glucose deprivation [28]. Several studies have 
provided evidence that metformin can slow or improve cogni-
tive function decline [22]; however, whether metabolic control 
by metformin contributes to its beneficial effects on cognitive 
function remains unclear. Some studies have failed to confirm that 
cognition is improved in T2DM patients even after good glycemic 
control [29]. In a study by Mussell et al. [30], despite near normo-
glycemia levels for over 3 months in diabetic subjects, no specific 
effects on cognitive performance were observed when compared 
to controls. These findings suggest that glycemic control might 
not be essential for the beneficial effect of metformin on cognitive 
performance in patients. 
Recently, Row et al. [31], investigated the effect of a novel met-
formin derivative, HL271, on molecular oscillations of clock genes 
and metabolic regulation in a diet-induced obesity mouse model 
and compared these effects with those of metformin. A time-
course experiment showed that HL271, which phosphorylates 
AMPK, significantly increased AMPK phosphorylation levels fast-
er and at much lower concentrations than metformin. Although 
HL271 acts by activating AMPK to regulate the circadian period 
and clock gene expression, HL271 did not affect the expression 
of key factors involved in glucose homeostasis such as glucose-
6-phosphatase (G6pase) or phosphoenolpyruvate carboxykinase 
1 (Pck1). Moreover, HL271 did not affect metabolic regulation 
assessed by body weight, blood glucose, insulin levels and lipid 
metabolite content in mice with diet-induced obesity, whereas 
metformin treatment significantly reduced all of them. In sum, 
HL271 is a potent AMPK activator, but its physiological effects are 
different from those of metformin, specifically regarding meta-
bolic control [31].
47www.enjournal.orghttps://doi.org/10.5607/en.2018.27.1.45
The Effect of HL271 on Aging-induced Cognitive Decline
Here, we utilized both metformin and HL271 for the behavioral 
assessment of cognitive function in mouse models of aging. Body 
weight changes before and two months after drug treatment as 
well as general locomotion and anxiety were measured. For cogni-
tive function, spatial working memory, novel object recognition 
memory and contextual memory were evaluated. Tissues were 
collected at the end of these studies to measure AMPK enzyme 
activity levels. 
MATERIALS AND METHODS 
Animals
Animal care and experimental procedures followed the guide-
lines of the Institutional Animal Care and Use Committee of the 
Institute of Basic Science (IBS). Experiments were performed 
with male and female C57BL/6J mice (12~16 weeks of age for the 
young group and 20~22 months of age for the old groups). Group-
housed mice were separated into single cages for acclimatization 
one month before beginning drug treatment. Mice were housed 
under controlled temperature and light conditions (23oC, 12-h 
light:12-h dark cycle). Experiments were performed during the 
light phase. The old mice were divided into three groups and orally 
treated with normal drinking water (control), metformin solution 
(100 mg/kg), or HL271 solution (50 mg/kg) for 2 months.
Open field test (OFT)
OFT was performed as previously reported [32]. Briefly, mice 
were placed in the center of an open field chamber (40×40×40 
cm3) illuminated with 10 lux light and remained in the box for 30 
min. After the test, each mouse was returned to its home cage, and 
the box was wiped clean using 70% ethanol and distilled water. 
Mouse activity was recorded and analyzed by using Ethovision 9.0 
(Noldus Information Technology). Total distance moved for the 
30 min and the duration spent in the center area for the first 5 min 
were analyzed to determine general locomotion and anxiety. 
Novel object recognition test (NORT)
NORT was performed using previously described methods [33] 
with minor modifications. NORT was performed in the same box 
as the open field test (40×40×40 cm3); the box was illuminated 
with 10 lux light. On the first day of the experiment, the sample 
phase, two identical objects were presented to each mouse. The 
mouse was placed on one side of the open field box and allowed 
to freely explore for 20 min. After 24 hours, the test phase was 
conducted; in this phase, one of the old objects was replaced by a 
novel object and presented to each mouse for 10 min. To remove 
olfactory stimuli, chamber and objects were cleaned with 70% 
ethanol and distilled water after testing each animal. The results 
are expressed as a discrimination ratio of the time spent with the 
novel object to the total exploration time.
Y-maze test
Spatial working memory was assessed by using the Y-maze spon-
taneous alternation test as previously described with minor modi-
fications [34]. The Y-maze consists of three arms of equal size. The 
arms were 32.5 cm long, 3 cm wide and 15 cm high. The Y-maze 
test was performed under 10 lux lighting conditions. Each mouse 
was placed at the end of one arm and was free to explore the arena 
for 8 min. A mouse was considered to make a triad when it entered 
all 3 arms consecutively. The maze was cleaned thoroughly with 70 
% ethanol solution and distilled water between tests. As a measure 
of working memory, the percentage of spontaneous alternation 
performance (%SAP) was calculated as the number of triads di-
vided by the maximum possible alternations (total number of arm 
entries -2) X 100. 
Contextual Fear Conditioning (CFC)
CFC was performed as previously described [32] with minor 
modifications. Training consisted of placing the mice in the cham-
ber for a period of 180 s, after which a 1 s foot shock (0.5 mA) 
without an auditory tone was delivered through the rod floor. Mice 
were returned to their home cage 60 s after the shock ended. For 
hippocampal-dependent memory tests, 24 hours after fear con-
ditioning, mice were placed in the same conditioning context for 
five min. Freezing was assessed automatically using EthoVision 9.0 
software (Noldus Information Technology). Freezing was defined 
as lack of any movement other than respiration and heartbeat for a 
1 s interval and is presented as a percentage of the total test time.
Immunochemistry
For diaminobenzidine-based immunohistochemical labeling, 
free-floating sections were initially treated with 0.3 % H2O2 diluted 
in phosphate-buffered saline (PBS) to inhibit endogenous peroxi-
dase activity and then blocked (30 min) with 5 % normal goat se-
rum diluted in PBS with 0.1% Triton X-100 (PBST). Sections were 
then incubated overnight with an antibody against AMP-activated 
kinase (p-AMPK alpha (T172), rabbit monoclonal, 1;10,000, Cell 
Signaling). After sections were incubated with a biotinylated sec-
ondary antibody, the tissues were processed using the ABC label-
ing technique (Vector Labs, Burlingame, CA, USA), and nickel-
intensified diaminobenzidine was used to visualize the signal. 
Sections were then mounted, dehydrated in xylene, and sealed with 
Permount (Sigma). Images were acquired using a Nikon inverted 
microscope (Nikon, Eclipse Ti), and data analyses were performed 
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Fig. 1. Behavior analysis in young and aged mice. (A) Locomotor activity. The total distance traveled was not significantly different between the two 
groups (young mice, 17420±753.1 cm, n=15; aged mice, 17080±674.5 cm, n=17). p=0.7402, student’s t-test, two-tailed. (B) Anxiety. The two groups spent 
similar durations in the center of the open field; there was no significant difference in the anxiety levels (young mice, 365.7±31.15 s, n=15; aged mice, 
419.2±35.52 s, n=17). p=0.2714, student’s t-test, two-tailed. (C) The discrimination ratio in the young mice (0.7680±0.02941, n=15) was significantly 
higher than that in the aged mice (0.6353±0.03828, n=17) in the novel object recognition task; the aged mice exhibited a decline in recognition memory 
compared to the young mice. *p=0.0115, student’s t-test, two-tailed. (D) Spatial working memory was analyzed by Y-maze tests in both young and aged 
mice. Bars represent the percentage of spontaneous alternation performance (%SAP). The percentage of spontaneous alternation performance (%SAP) 
of the aged mice (54.74±3.174%, n=17) was less than that of the young mice (64.29±2.425%, n=15). *p=0.0259, student’s t-test, two-tailed. (E) The freez-
ing level (%) indicates the percentage of time spent freezing in the 24-h post-fear conditioning test. The aged mice (31.03±2.841%, n=17) and the young 
mice (35.59±3.579%, n=15) did not differ in their freezing levels (%). p=0.3216, student’s t-test, two-tailed. Data are presented as the mean±SEM.
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with ImageJ. The dorsal hippocampus was selected to measure 
intensity. The intensity values of the corpus callosum were then 
measured and subtracted as the background intensity. Values from 
2 hemispheres from the dorsal hippocampus were averaged, and 3 
consecutive sections from each mouse were averaged. A total of 4 
to 5 mice from each group were averaged for statistical analyses.
RESULTS
Aged mice showed normal locomotor activity and anxiety
Before we tested the efficacy of the AMPK activators metformin 
and HL271 in inhibiting age-associated cognitive decline, we 
needed to confirm that C57BL/6J mice, a common laboratory 
mouse strain, showed significant cognitive decline with age. To 
that end, we divided C57BL/6J mice into two groups, young (3~4 
months) and aged (20~22 months) mice, and performed various 
memory tasks, such as the novel object recognition test (NORT), 
Y-maze and contextual fear conditioning (CFC). Before the 
memory tasks, the mice were subjected to an open field test (OFT) 
to observe their general behaviors, such as spontaneous locomo-
tion and anxiety. The total distance the mice freely explored in the 
open-field arena was measured as its spontaneous locomotion, 
and the time spent in the center of the arena for the first 5 min of 
the OFT was measured as its anxiety level. The results showed no 
significant differences between young and aged mice for both lo-
comotion (student’s t-test; t=0.3346, df=30, p=0.7402; Fig. 1A) and 
anxiety (student’s t-test; t=1.12, df=30, p=0.2716; Fig. 1B), indicat-
ing that the motor activity and anxiety levels of the aged mice in 
our study were within a normal range. 
Aged mice showed impaired novel object recognition mem-
ory and spatial working memory 
To test novel object recognition memory, mice were first placed 
in an open arena containing two of the same objects (sample 
phase). Twenty-four hours later (test phase), one of the familiar 
objects was replaced with a novel object to evaluate novel object 
recognition memory, a natural exploratory behavior in rodents. 
The aged mice explored the novel object significantly less than 
the young mice, indicating that recognition memory in the aged 
mice was significantly decreased (student’s t-test; t=2.693, df=30, 
*p=0.0115; Fig. 1C). In the Y-maze task, when the percentage of 
alternations per group was compared to the chance level of 50%, 
both groups performed better than the chance level, which was 
indicative of functional working memory. Although aged mice 
had functional working memory, their spatial working memory 
was significantly attenuated compared to that of the young group 
(student’s t-test; t=2.345, df=30, *p=0.0259; Fig. 1D). Regarding 
contextual fear memory, the freezing level (%) during the contex-
tual retrieval test 24 hours after the conditioning represents the 
successful retention of hippocampal-dependent contextual fear 
memory. There was no significant difference in the freezing levels 
between the young and aged mice in the 24-h memory test, sug-
gesting that there were no significant age-related impairments 
in contextual fear memory in the aged group (student’s t-test; 
Fig. 2. Average water intake and change in 
body weight with drug treatment in aged 
mice. (A) Chemical structures of metfor-
min and HL271. (B) Average water intake 
per day. The mean daily water intake was 
no different among all three groups (one-
way ANOVA; F (2, 28)=1.418, p=0.2590). 
Water, 5.355±0.2025 ml/day, n=12; met-
formin, 4.915±0.2153 ml/day, n=9; HL271, 
4.839±0.3024 ml/day, n=10. (C) Mean body 
weight changes (body weight on the last day 
of oral drug treatment – body weight on 
the first day of oral treatment). Changes in 
body weights were not significantly different 
among all three groups (one-way ANOVA; F 
(2, 28)=2.0, p=0.1543, water, 0.2083±0.1823 
g, n=12; metformin, 0.3889±0.4238 g, n=9; 
HL271, -0.69±0.5677 g, n=10). Data are pre-
sented as the mean±SEM.
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Fig. 3. Behavior analysis after drug treatment in aged mice. (A) Locomotor activity. The total distance traveled was not significantly different among 
the three groups (one-way ANOVA; F (2,33)=0.4074, p=0.6687; water, 17080±674.5, n=17, metformin, 16400±1163, n=9, HL271, 16060±873.5, n=10). 
(B) Anxiety. All groups spent similar durations in the center; there was no significant difference in the anxiety levels (one-way ANOVA; F (2,33)=0.4074, 
p=0.6687; water, 419.3±35.53, n=17, metformin, 379.6±40.19, n=9, HL271, 447.4±63.66, n=10). (C) Novel object recognition memory test. One-way 
ANOVA; F (2,33)=3.655, p=0.0368. Post hoc Bonferroni’s multiple comparisons unveiled a significant difference between water (0.6353±0.03835, n=17) 
and HL271-treated mice (0.7849±0.03410, n=10). *p=0.0447. There was no significant difference between the water and metformin-treated group 
(0.7389±0.05256, n=9), p=0.2920. (D) Y-maze test. One-way ANOVA; F (2,33)=3.52, p=0.0412. Post hoc Bonferroni’s multiple comparisons unveiled 
significant differences between water (54.74±3.174%, n=17) and HL271-treated mice (69.76±3.518%, n=10), *p=0.0423. There was no significant differ-
ence between the water and metformin-treated group (57.14±6.586%, n=9). p>0.9999. (E) Contextual fear memory test. One-way ANOVA; F (2,33)=5.17, 
p=0.0111. Post hoc Bonferroni’s multiple comparisons unveiled significant differences between water (31.03±2.841%, n=17) and HL271-treated mice 
(45.72±4.375%, n=10), *p=0.0152. There was no significant difference between the water and metformin-treated group (41.91±3.822%, n=9). p=0.1171. 
Data are presented as the mean±SEM.
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t=1.008, df=30, p=0.3216; Fig. 1E). Altogether, these results indicate 
that the C57BL/6J strain used in our study clearly showed an age-
associated cognitive decline in novel object recognition memory 
and spatial working memory, suggesting that our age grouping and 
behavior schemes were appropriate for studying the efficacy of 
AMPK activators. 
Metformin and HL271 did not affect body weight, general 
locomotion, or anxiety
In a separate experimental series, the groups of aged mice were 
treated with normal drinking water (control group), metformin 
(Fig. 2A, 100 mg/kg) or HL271 (Fig. 2A, 50 mg/kg) for up to 2 
months. The average water intake was no different among all three 
groups (one-way ANOVA; F(2, 28)=1.418, p=0.2590; Fig. 2B). We 
adjusted the drug dosage according to the average water intake 
during the habituation period. The changes in body weights were 
not significantly different among the three groups (one-way ANO-
VA; F(2, 28)=2, p=0.1543; Fig. 2C). As shown in Fig. 3A and 3B, 
neither the locomotor activity (one-way ANOVA; F(2,33)=0.4071, 
p=0.6687) nor anxiety (one-way ANOVA; F(2, 33)=0.4386, 
p=0.6486) were significantly different among the three groups 
during the OFT. 
Only HL271 significantly attenuated the aging-induced de-
cline in novel object recognition memory and spatial work-
ing memory
During the novel object recognition task, the discrimination ratio 
in the HL271-treated mice group was higher than that in the mice 
treated with water, indicating that HL271 treatment improved 
recognition memory in the aged mice (one-way ANOVA; F (2, 
33)=3.655, *p=0.0368; Fig. 3C). For the spontaneous alternation 
task in the Y-maze, HL271 treatment significantly enhanced the 
spatial working memory compared to treatment with water (one-
way ANOVA; F (2, 33)=3.52; *p=0.0412, Fig. 3D). Interestingly, in 
the CFC task, the freezing level was significantly increased in the 
HL271-treated group compared to that in the water-treated group 
(one-way ANOVA; F (2, 33)=5.17; *p=0.0111, Fig. 3E). Since there 
was no significant difference between the young and aged groups 
during the contextual fear memory retrieval test (student’s t-test; 
p=0.3216; Fig. 1E), the enhancement of contextual fear memory 
by HL271 indicates that this drug improved memory in the aged 
mouse group to some degree.
Only HL271 significantly increased AMPK activation in the 
hippocampus of aged mice
Following the behavioral assays, immunohistochemistry was 
performed to measure AMPK activation. The hippocampus 
has been suggested to be associated with synaptic plasticity and 
Fig. 4. AMPK activation in the mouse brain. (A) AMPK activation levels in young and aged mice. Upper: representative images of phospho-AMPK 
(pAMPK) expression in young and aged mice. Lower: quantification of pAMPK expression levels. Young (100±9.73, n=4) and aged (51.56±11.27, n=4). 
*p=0.0174, student’s t-test, two-tailed. (B) Effects of HL271 on AMPK activation. Upper: representative images of pAMPK expression in the three groups. 
Lower: quantification of pAMPK expression levels. One-way ANOVA; F (2, 11)=4.142, *p=0.0456. Post hoc Bonferroni’s multiple comparisons unveiled 
significant differences between the water (100.4±11.72, n=4) and HL271-treated mice (192.4±23.52, n=5), *p=0.0484. There was no significant difference 
between the water and metformin-treated group (138.6±25.45, n=5), p=0.7907. (C) Image describing the pAMPK intensity analysis. Using the freehand 
selection tool in ImageJ, a line was drawn to select the whole hippocampus, and the mean intensity was measured. A square box of a fixed size was used 
to measure the background intensity for each slice. Data are presented as the mean±SEM.
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memory, including spatial working [35], novel object recognition 
[36] and contextual fear memories [37]. Immunohistochemical 
analyses revealed that AMPK activation in the hippocampus was 
significantly lower in the aged mice than in the young mice (stu-
dent’s t-test; t=3.254, df=6, *p=0.0174; Fig. 4A and C). When the 
AMPK activators metformin and HL271 were administered to 
the aged mice, both the metformin and HL271 treatment groups 
expressed greater levels of AMPK phosphorylation than the water 
group, but this change was only significant in the HL271 treatment 
group (one-way ANOVA; F(2,34)=3.69, *p=0.0354; Fig. 4B and 
C). These results suggest that AMPK activation might be involved 
in the mechanism by which treatment with 50 mg/kg HL271 im-
proved the aging-induced cognitive decline. 
DISCUSSION
In this study, we tested the efficacy of two different AMPK ac-
tivators, metformin and HL271, on aging-induced cognitive de-
cline. The current study used the Y-maze and NORT, which clearly 
depicted age-associated declines in spatial working memory and 
novelty recognition memory in aged mice. The drug treatment 
assays revealed that 50 mg/kg HL271 not 100 mg/kg metformin 
significantly inhibited the aging-induced cognitive decline. In 
addition, HL271 enhanced hippocampal-dependent contextual 
memory. Altogether, our data suggest that HL271 is a potential 
therapeutic agent to treat aging-associated cognitive impairment 
or related diseases, such as dementia and AD.
Aging mice have been extensively used for investigating age-
dependent memory decline and its underlying mechanisms and 
for developing drugs that potentially target aging and aging-
associated cognitive dysfunctions. Several studies have shown 
extensive impairments in aging mice, including impairments in 
spatial working memory [38-40], object recognition memory [41], 
contextual memory [42, 43] and motor coordination [44-46]. We 
found that C57BL/6J mice clearly showed impairments in novelty 
recognition memory (Fig. 1C) and spatial working memory (Fig. 
1D) according to behavior tests at 20~22 months of age. However, 
we did not see any differences in locomotion (Fig. 1A), anxiety 
(Fig. 1B) or fear-related contextual memory (Fig. 1E) between the 
young (3~4 months) and aged (20~22 months) mouse groups. 
Although many researchers have reported impairments in loco-
motion and fear-related behaviors, several studies did not find sig-
nificant differences in these behaviors, as we observed in this study 
[47, 48]. Thus, a possible explanation for these behavior discrepan-
cies is that the environment, food, bedding or housing may affect 
the general behaviors of animals maintained in a facility. However, 
we found significant impairments in spatial working memory and 
novel object recognition memory in the aged group compared to 
those in the young group, suggesting that our age grouping and be-
havior schemes were appropriate for studying the efficacy of drugs 
in the treatment of aging-induced cognitive decline.
Because cognitive impairment and T2DM are common disor-
ders in the elderly, metformin and other diabetes medications have 
been tested in both humans and rodents to determine the poten-
tial efficacy of these drugs in the treatment of aging-related cogni-
tive function decline [49, 50]. Particularly, metformin (100 mg/
kg) has been used to improve longevity, muscle tone and cognitive 
function without any adverse effects on organs and the brain [51-
53]. However, the efficacy of metformin in improving cognitive 
function is still controversial. Some studies have shown that ad-
ministration of metformin rather increased the risk of cognitive 
impairments [54-56]. A recent study [56] reported a deleterious 
effect of metformin on spatial memory and visual acuity. In that 
study, mice received metformin at higher doses (~219~297 mg/
kg/day) and for a longer duration (3 months) than the mice in our 
study (100 mg/kg/day and 2 months). In this study, we observed 
neither deleterious effects nor beneficial effects of metformin on 
cognitive function (Fig. 3C~E). Only HL271 (50 mg/kg) showed 
significant effects on the aging-induced cognitive decline. Since 
HL271 is known to activate AMPK, we investigated the expres-
sion of phosphorylated AMPK two months after oral treatment 
with each drug and determined that treatment with 50 mg/kg 
HL271 yielded a higher level of AMPK phosphorylation in the 
hippocampus than treatment with 100 mg/kg metformin (Fig. 
4B). This observation indicates that the improvement in cognitive 
function induced by HL271 in the aged mouse group might be 
AMPK-dependent. However, HL271 may also act in an AMPK-
independent manner. Although there are no reports that have 
investigated the AMPK-independent effects of HL271, metformin 
is known to regulate mitogen signaling (mTORC1 and ERK) and 
DNA synthesis in pancreatic cancer cells through dose-dependent 
AMPK-dependent and -independent pathways [57]. Metformin 
also regulates adipogenesis through AMPK-dependent and -inde-
pendent mechanisms [58]. Therefore, more research is needed to 
identify whether the improving effect of HL271 on aging-induced 
cognitive decline is through AMPK-dependent action. An ex-
tended study using AMPK inhibition, such as through hippocam-
pal tissue-specific AMPK knockout or expression of a dominant-
negative (DN) AMPK, along with HL271 treatment will be crucial 
to show a direct causal relationship between AMPK activity and 
the beneficial effect of HL271 on aging-induced cognitive decline. 
What are possible reasons for the differences in the effects of 
HL271 and metformin on cognitive function in the aged mouse 
group? Many researchers consider aging-induced metabolic dys-
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regulation to be a key factor that initiates cognitive decline. There-
fore, extensive studies have focused on drugs that regulate or are 
linked to metabolism or associated pathways for treating demen-
tia. Therefore, metformin has been considered as a potential drug 
due to its pleiotropic effects on metabolism, including sensitization 
to insulin, increase in glucose uptake, and decrease in hepatic glu-
cose synthesis [59]. However, in this study, we found that HL271 
was more effective than metformin at attenuating aging-induced 
cognitive decline. Currently, there is limited knowledge regarding 
the underlying mechanisms of the effects of HL271 on cogni-
tive function. According to the recent results showing that, unlike 
metformin, HL271 is not involved in metabolic control [31], we 
considered that metabolic regulation might not be the important 
factor necessary to improve cognitive function in the aged mouse 
group. As a more potent AMPK activator, one possible mecha-
nism of HL271 on cognitive function may be through activation 
of AMPK pathways that are not restricted to the maintenance of 
energy metabolism. In fact, several studies have shown that AMPK 
activation can coordinate autophagocytosis of damaged structures 
[60], increase tissue resistance against stressors such as oxidative 
stress [61] and endoplasmic stress [62] and suppress inflammatory 
disorders [63]. These processes controlled by AMPK activation 
are important for the regulation of the aging process [64] and 
cognitive function [65, 66]. Interestingly, HL271 induced a greater 
increase in AMPK phosphorylation than metformin in the aged 
mouse group (Fig. 4B), and deficiency in the sensitivity of AMPK 
activation in aged tissues has been confirmed with different types 
of AMPK activators [67, 68]. Therefore, unknown upstream sig-
naling pathways might be uniquely activated by HL271 and not 
by metformin to disinhibit systems suppressing AMPK activation 
in aged tissues, i.e., protein phosphatase 2A (PP2A), PP2Ca and 
protein phosphatase, or Mg2+/Mn2+-dependent 1E (Ppm1E) [64]. 
In addition, distinct AMPK-independent signaling pathways are 
also possibly activated by HL271, which is as yet unclear. There-
fore, future studies are required to identify the underlying cellular 
and molecular mechanisms of the HL271-mediated improvement 
in cognitive function in the aged mouse. Although we did not see 
a significant improvement in cognitive function with metformin 
treatment, we observed a tendency for metformin to inhibit the 
impairments in novel object recognition memory (Fig. 3C) and 
to enhance contextual fear memory (Fig. 3E). Therefore, larger 
sample sizes are necessary to draw more concrete conclusions.
Altogether, our study demonstrates the outstanding effects of the 
newly synthesized AMPK activator HL271 on aging-induced cog-
nitive decline and raises the possibility of using HL271 as a future 
treatment for cognitive impairment and related diseases, such as 
AD and dementia.
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